Comparative Pharmacology
Head-to-head clinical analysis: INDOCIN versus MEASURIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDOCIN versus MEASURIN.
INDOCIN vs MEASURIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.
Measurin is an aspirin preparation that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin and thromboxane synthesis. This results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life approximately 4.5 hours (range 2.6–11.2 hours); prolonged in elderly and patients with hepatic impairment.
Plasma elimination half-life is 2-3 hours at low doses (antiplatelet) and increases to 15-30 hours at anti-inflammatory doses due to saturation of hepatic metabolism; clinical context: higher doses require longer dosing intervals to avoid accumulation.
Renal (60% as unchanged drug and glucuronide conjugates), biliary/fecal (33% via enterohepatic circulation).
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid) accounts for >90% of elimination; minor biliary/fecal excretion (<5%) occurs.
Category C
Category C
NSAID
NSAID